Status:
RECRUITING
Establish Diagnostic and Prognostic Models for Preclinical AD Patients Based on Multimodal MRI, Behavioral, Genetic, and Plasma Biomarkers
Lead Sponsor:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Conditions:
Alzheimer Disease, Late Onset
Mild Cognitive Impairment
Eligibility:
All Genders
50-79 years
Brief Summary
To establish the diagnostic and prognostic models that could help the preclinical identification of subjects at higher risk of clinical progression to mild cognitive impairment and dementia based on c...
Detailed Description
Alzheimer's disease (AD) is a global concern. Due to the lack of effective therapeutic methods targeting late-stage AD patients, it is critical to investigate brain alterations in the preclinical stag...
Eligibility Criteria
Inclusion
- The inclusion criteria were 50-79 years old and having 8 or more years of education.
Exclusion
- Participants with a history of stroke, other neurological disorders that could lead to cognitive impairment (Parkinson's disease, encephalitis, epilepsy, brain tumors, etc.), severe anxiety or depression, and contraindications for magnetic resonance imaging (MRI) were not enrolled.
Key Trial Info
Start Date :
September 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2027
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT06561906
Start Date
September 1 2020
End Date
December 1 2027
Last Update
August 20 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China, 210008